ASIC data shows total shorting at about 6% with ongoing daily manipulation to force the share price down to this incredibly low valuation. A pre-FDA approval valuation and pre-generating about $110 Million Revenue and about $40 Million NPAT which are absolute peer leading financials that nearly every other Biotech could only dream about. This has of course happened while running a blockbuster phase 3 which will complete and give out results next year with an already FDA approved drug and distribution network in the States. Vitiligo not priced in at all, let alone a single cent of revenue from an Ozempic potential real tanning photo cosmetic also announced for next year in Bulletin 2. What will Vitiligo approval do? Clinuvel says around $800 Million AUD in years 1 - 2! What would happen if Clinuvel bought back and deleted 1.5 Million shares as stated? What if the shorters bought back their 3 Million fake Sell shares with real shares? 4.5 Million shares on the Buy side with only 50 Million CUV out there. Interesting stuff, I still reckon shorters are angling for a set up for a cheap takeover. Time will tell. Vitiligo program looking great and transformative.
All IMO DYOR
CUV Price at posting:
$9.71 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)